Press Release

For Immediate Release

Cambridge, MA, December 19, 2023 — Biozyme Corporation®, a global provider of innovative pharmaceutical solutions, announced today that it has run out of letter combinations for all future drugs, including those under development. “With the release of our new cutting edge SBS (shy bladder syndrome) medication, Ininossssdzz©®, we have exhausted all reasonable length permutations of the 26 letter English alphabet,” said Bryce Fiasco, Chief Appellation Officer for Biozyme©®℗. “We need to start exploring entirely new character sets.” The CAO adds, “Biozyme©®℗Ø is not facing this dilemma alone. The entire industry has depleted all combinations of characters 12 letters or less.”

Biozyme©®℗Ø֍ was not forthcoming with any details regarding their plans going forward. Rumor has it they will be utilizing numbers, non-English alphabets, heiroglyphics, emojis, animal noises, as well as tones picked up by radio telescopes aimed into deep space.

“At Biozyme©®℗Ø֍♂, our core competency has always been innovation and we’re very excited to move ahead into previously uncharted sobriquet territory. No longer will we be restricted by the arbitrary limitations of an archaic collection of characters.” It is expected that the first drug employing the new naming paradigm will be Biozyme’s©®℗Ø֍♂☺groundbreaking treatment for the relief of side effects of their drug used to lessen negative reactions to its medication to treat hangnails caused by the use of their mRNA dandruff therapy.

“We’re sure that the consumers of our products will be quite comfortable with the new drug names,” said Chief Rationalization Officer Hymie Slamm. “After all, none of our current offerings are pronounceable by humans.”